{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:01:10Z","timestamp":1790042470443,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004434","name":"University of Florence","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003407","name":"Italian Ministry for University and Research","doi-asserted-by":"crossref","award":["PRIN 2010\u20132011"],"award-info":[{"award-number":["PRIN 2010\u20132011"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003407","name":"Italian Ministry for University and Research","doi-asserted-by":"crossref","award":["20103779_04"],"award-info":[{"award-number":["20103779_04"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003056","name":"Ente Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","award":["2013.0664A2202.3926"],"award-info":[{"award-number":["2013.0664A2202.3926"]}],"id":[{"id":"10.13039\/501100003056","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Camerino, Italy"},{"name":"Italian Ministry for University and Research, Rome, Italy"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejmech.2016.09.076","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T05:48:18Z","timestamp":1475128098000},"page":"611-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes"],"prefix":"10.1016","volume":"125","author":[{"given":"Daniela","family":"Poli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Falsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Varani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Pedata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Dal Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajiroghene","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Palchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bettazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Catarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Colotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.09.076_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International union of Pharmacology LXXXI. Nomenclature and classification of adenosine receptors. An up date","volume":"63","author":"Fredholm","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2016.09.076_bib2","first-page":"129","article-title":"P1 and P2 purine and pyrimidine receptor ligands","volume":"Vol. 151\/1","author":"Jacobson","year":"2001"},{"key":"10.1016\/j.ejmech.2016.09.076_bib3","first-page":"413","article-title":"Receptors for purines and pyrimidines","volume":"50","author":"Ralevic","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2016.09.076_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"M\u00fcller","year":"2011","journal-title":"Biochimica Biophysica Acta"},{"key":"10.1016\/j.ejmech.2016.09.076_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/pr.113.008540","article-title":"The A3 adenosine receptor: history and perspectives","volume":"67","author":"Borea","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2016.09.076_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjp.0705442","article-title":"Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in\u00a0vitro hippocampus: role of adenosine receptors","volume":"140","author":"Pugliese","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib7","first-page":"768","article-title":"Adenosine receptors in health and disease","volume":"74","author":"Pugliese","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib8","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1021\/jm070123v","article-title":"Arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies","volume":"50","author":"Colotta","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib9","first-page":"805198","article-title":"Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia","author":"Pedata","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2016.09.076_bib10","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1021\/jm0504149","article-title":"1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives","volume":"48","author":"Catarzi","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib11","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.bmc.2008.04.039","article-title":"Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 Adenosine Receptor Antagonists","volume":"16","author":"Colotta","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1021\/jm8014876","article-title":"Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies","volume":"52","author":"Colotta","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bmc.2012.10.031","article-title":"Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies","volume":"21","author":"Catarzi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib14","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1021\/jm070852a","article-title":"Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study","volume":"50","author":"Morizzo","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib15","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1021\/jm101328n","article-title":"The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists","volume":"54","author":"Poli","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib16","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1021\/jm400068e","article-title":"2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation","volume":"56","author":"Squarcialupi","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bmc.2014.11.033","article-title":"1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies","volume":"23","author":"Catarzi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejmech.2015.04.010","article-title":"Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the desin of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation","volume":"96","author":"Varano","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ejmech.2014.07.060","article-title":"7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigation at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies","volume":"84","author":"Squarcialupi","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2174\/156802610791293109","article-title":"A3 receptor ligands: past, present and future trends","volume":"10","author":"Taliani","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejmech.2015.12.019","article-title":"5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors","volume":"108","author":"Federico","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ejmech.2015.01.046","article-title":"A\u00a0facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists","volume":"92","author":"Venkatesan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib23","first-page":"117","article-title":"Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors","volume":"108","author":"Squarcialupi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/med.21344","article-title":"History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents","volume":"35","author":"Preti","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2016.09.076_bib25","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.bmcl.2005.05.086","article-title":"2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1","volume":"15","author":"Matasi","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.09.076_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1752-153X-6-83","article-title":"Fluorescent property of 3-hydroxymethyl imidazo[1,2-a]pyridine and pyrimidine derivatives","volume":"6","author":"Velazquez-Olvera","year":"2012","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.ejmech.2016.09.076_bib27","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1021\/jm070721+","article-title":"4-[\u03c9-[4-Arylpiperazin-1-yl]alkoxy]phenyl)imidazo[1,2-a]pyridine derivatives: fluorescent high-affinity dopamine D3 receptor ligand as potential probe for receptor visualization","volume":"50","author":"Leopoldo","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib28","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bmcl.2012.01.074","article-title":"Imidazo[1,2-a]pyrazines as novel PI3K inhibitors","volume":"22","author":"Martinez Gonzalez","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.09.076_bib29","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1002\/chem.201200967","article-title":"[Cu(dap)2Cl] As an efficient visible-light-driven photoredox catalyst in carbon-carbon bond-forming reactions","volume":"18","author":"Pirtsch","year":"2012","journal-title":"Chem. - A Eur. J."},{"key":"10.1016\/j.ejmech.2016.09.076_bib30","unstructured":"C. Sablayrolles, P.A. Bonnet, G. Cros, J.P. Chapat, M. Boucard. 8-Alkylaminoimidazo[1,2-a]pyrazine Derivatives, Their Preparation, and Their Application in Therapy. WO 8804298 A1 19880616."},{"key":"10.1016\/j.ejmech.2016.09.076_bib31","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/138161208784480081","article-title":"A2A adenosine receptor and its modulators: an overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists","volume":"14","author":"Cristalli","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2016.09.076_bib32","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1021\/jm4011669","article-title":"Adenosine A2A receptor as a drug discovery target","volume":"57","author":"de Lera Ruiz","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib33","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2016.09.076_bib34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2174\/156802610791293145","article-title":"Adenosine receptor modeling: what does the A2A crystal structure tell us?","volume":"10","author":"Dal Ben","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib35","first-page":"63","article-title":"Structure and function of G-protein-coupled receptors studied using sequence analysis, molecular modeling, and receptor engineering: adenosine receptors","volume":"3","author":"Costanzi","year":"2007","journal-title":"Front. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2016.09.076_bib36","unstructured":"Molecular Operating Environment; C.C.G., Inc., 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3."},{"key":"10.1016\/j.ejmech.2016.09.076_bib37","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1021\/jm960482i","article-title":"Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype","volume":"39","author":"Kim","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00128336","article-title":"MOPAC: a semiempirical molecular orbital program","volume":"4","author":"Stewart","year":"1990","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2016.09.076_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10822-008-9250-3","article-title":"Interaction force diagrams: new insight into ligand-receptor binding","volume":"23","author":"Shadnia","year":"2009","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2016.09.076_bib40","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1016\/j.bmc.2010.09.038","article-title":"Molecular modelling study on potent and selective adenosine A3 receptor agonists","volume":"18","author":"Dal Ben","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2193-9616-1-24","article-title":"Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor","volume":"1","author":"Dal Ben","year":"2013","journal-title":"Silico Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib42","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1471-4159.2006.03823.x","article-title":"Sustained elevation of extracellular adenosine and activation of A1 receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in\u00a0vitro","volume":"97","author":"Pearson","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1476-5381.2009.00218.x","article-title":"The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices","volume":"157","author":"Pugliese","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1039\/an9830801067","article-title":"Relative fluorescence quantum yields using a computer controlled luminescence spectrometer","volume":"108","author":"Williams","year":"1983","journal-title":"Analyst"},{"key":"10.1016\/j.ejmech.2016.09.076_bib45","series-title":"Principles of Fluorescence Spectroscopy","author":"Lakowicz","year":"1999"},{"key":"10.1016\/j.ejmech.2016.09.076_bib46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jcc.540110405","article-title":"MacroModel e an integrated software system for modeling organic and bioorganic molecules using molecular mechanics","volume":"11","author":"Mohamadi","year":"1990","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib47","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/ja00124a002","article-title":"A\u00a0second generation force field for the simulation of proteins, nucleic acids, and organic molecules","volume":"117","author":"Cornell","year":"1995","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2016.09.076_bib48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","article-title":"Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<520::AID-JCC2>3.0.CO;2-W","article-title":"Merck Molecular Force Field. II. MMFF94 van der Waals and Electrostatic Parameters for Intermolecular Interactions","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<553::AID-JCC3>3.0.CO;2-T","article-title":"Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<587::AID-JCC4>3.0.CO;2-Q","article-title":"Merck molecular force field. IV. Conformational energies and geometries for MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<616::AID-JCC5>3.0.CO;2-X","article-title":"Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X","article-title":"MMFF VI. MMFF94s option for energy minimization studies","volume":"20","author":"Halgren","year":"1999","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T","article-title":"MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force Fields for conformational energies and for intermolecular-interaction energies and geometries","volume":"20","author":"Halgren","year":"1999","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2016.09.076_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2013.10.011","article-title":"Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch","volume":"87","author":"Dal Ben","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuropharm.2014.01.028","article-title":"Trr469, a potent A1 adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropatic pain models in mice","volume":"81","author":"Vincenzi","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2016.09.076_bib57","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/art.24794","article-title":"Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate","volume":"60","author":"Varani","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2016.09.076_bib58","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0026-895X(24)26507-X","article-title":"[3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors","volume":"57","author":"Varani","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib59","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bcp.2005.08.018","article-title":"Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors","volume":"70","author":"Varani","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.bjp.0706646","article-title":"A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in\u00a0vitro","volume":"147","author":"Pugliese","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.09.076_bib61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(01)00374-0","article-title":"The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events","volume":"108","author":"Anderson","year":"2001","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.ejmech.2016.09.076_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.jcbfm.9600569","article-title":"Direct, live imaging of cortical spreading depression and anoxic depolarization using a fluorescent, voltage-sensitive dye","volume":"28","author":"Farkas","year":"2008","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.ejmech.2016.09.076_bib63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1471-4159.1993.tb03566.x","article-title":"Investigations into the adenosine outflow from hippocampal slices evoked by ischemialike conditions","volume":"61","author":"Pedata","year":"1993","journal-title":"J.\u00a0Neurochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416308121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416308121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T21:51:08Z","timestamp":1749592268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416308121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":63,"alternative-id":["S0223523416308121"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.076","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}